{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:10:27Z","timestamp":1771535427323,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005485","name":"American College of Cardiology Foundation\u2019s","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005485","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cardiovascular Data Registry"},{"name":"The Society of Thoracic Surgeons National Database"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Guideline-directed medical therapy (GDMT) is recommended before mitral valve transcatheter edge-to-edge repair (MTEER) in patients with heart failure (HF) and severe functional mitral regurgitation (FMR). Whether MTEER is being performed on the background of optimal GDMT in clinical practice is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with left ventricular ejection fraction (LVEF) &amp;lt; 50% who underwent MTEER for FMR from 23 July 2019 to 31 March 2022 in the Society of Thoracic Surgeons\/American College of Cardiology Transcatheter Valve Therapy Registry were identified. Pre-procedure GDMT utilization was assessed. Cox proportional hazards models were constructed to evaluate associations between pre-MTEER therapy (no\/single, double, or triple therapy) and risk of 1-year mortality or HF hospitalization (HFH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 4199 patients across 449 sites, beta-blockers, angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin receptor\u2013neprilysin inhibitors were used in 85.1%, 44.4%, 28.6%, and 19.9% before MTEER, respectively. Triple therapy was prescribed for 19.2%, double therapy for 38.2%, single therapy for 36.0%, and 6.5% were on no GDMT. Significant centre-level variation in the proportion of patients on pre-intervention triple therapy was observed (0%\u201361%; adjusted median odds ratio 1.48 [95% confidence interval (CI) 1.25\u20133.88]; P &amp;lt; .001). In patients eligible for 1-year follow-up (n = 2014; 341 sites), the composite rate of 1-year mortality or HFH was lowest in patients prescribed triple therapy (23.0%) compared with double (24.8%), single (35.7%), and no (41.1%) therapy (P &amp;lt; .01 comparing across groups). Associations persisted after accounting for relevant clinical characteristics, with lower risk in patients prescribed triple therapy [adjusted hazard ratio (aHR) 0.73, 95% CI .55\u2013.97] and double therapy (aHR 0.69, 95% CI .56\u2013.86) before MTEER compared with no\/single therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Under one-fifth of patients with LVEF &amp;lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no\/single therapy, triple and double therapy before MTEER were independently associated with reduced risk of mortality or HFH 1 year after intervention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad584","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T16:14:06Z","timestamp":1693066446000},"page":"4650-4661","source":"Crossref","is-referenced-by-count":18,"title":["Heart failure medical therapy prior to mitral transcatheter edge-to-edge repair: the STS\/ACC Transcatheter Valve Therapy Registry"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-8948","authenticated-orcid":false,"given":"Anubodh S","family":"Varshney","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University , Palo Alto, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miloni","family":"Shah","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreekanth","family":"Vemulapalli","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC , USA"},{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Kosinski","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankeet S","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Kaiser Permanente San Francisco Medical Center and Division of Research , San Francisco, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University , Palo Alto, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Hirji","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia M","family":"DeFilippis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Columbia University Irving Medical Center , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinak B","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine , Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Fiuzat","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick T","family":"O\u2019Gara","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine , Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Washington University in St Louis , St Louis, MO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M","family":"Givertz","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine , Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine , Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"key":"2023112102043498200_ehad584-B1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2023112102043498200_ehad584-B2","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"2023112102043498200_ehad584-B3","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"77","author":"Writing Committee Members","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023112102043498200_ehad584-B4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023112102043498200_ehad584-B5","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2023112102043498200_ehad584-B6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2023112102043498200_ehad584-B7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023112102043498200_ehad584-B8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023112102043498200_ehad584-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2023112102043498200_ehad584-B10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2015.12.046","article-title":"Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation","volume":"67","author":"Roth","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023112102043498200_ehad584-B11","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.amjcard.2014.03.049","article-title":"Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008","volume":"113","author":"Schneider","year":"2014","journal-title":"Am J Cardiol"},{"key":"2023112102043498200_ehad584-B12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jacc.2013.03.060","article-title":"The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies","volume":"62","author":"Carroll","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023112102043498200_ehad584-B13","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2021.07.058","article-title":"Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT registry","volume":"78","author":"Mack","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023112102043498200_ehad584-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"2023112102043498200_ehad584-B15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.0006-341X.2000.00909.x","article-title":"Interpreting parameters in the logistic regression model with random effects","volume":"56","author":"Larsen","year":"2000","journal-title":"Biometrics"},{"key":"2023112102043498200_ehad584-B16","doi-asserted-by":"crossref","first-page":"i189","DOI":"10.1136\/bmj.i189","article-title":"Inverse probability weighting","volume":"352","author":"Mansournia","year":"2016","journal-title":"BMJ"},{"key":"2023112102043498200_ehad584-B17","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jama.2023.7089","article-title":"Transcatheter mitral valve repair for degenerative mitral regurgitation","volume":"329","author":"Makkar","year":"2023","journal-title":"JAMA"},{"key":"2023112102043498200_ehad584-B18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jcin.2023.01.362","article-title":"Impact of transcatheter edge-to-edge mitral valve repair on guideline-directed medical therapy uptitration","volume":"16","author":"Adamo","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2023112102043498200_ehad584-B19","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/ejhf.2613","article-title":"Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation","volume":"24","author":"Higuchi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023112102043498200_ehad584-B20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2023112102043498200_ehad584-B21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl J Med"},{"key":"2023112102043498200_ehad584-B22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"2023112102043498200_ehad584-B23","first-page":"e231266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2023112102043498200_ehad584-B24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jchf.2023.03.009","article-title":"Guideline-directed medical therapy tolerability in patients with heart failure and mitral regurgitation: the COAPT trial","volume":"11","author":"Cox","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2023112102043498200_ehad584-B25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamacardio.2019.4665","article-title":"Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial","volume":"5","author":"DeVore","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2023112102043498200_ehad584-B26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjmed.2014.11.036","article-title":"Beta-blocker use and 30-day all-cause readmission in medicare beneficiaries with systolic heart failure","volume":"128","author":"Bhatia","year":"2015","journal-title":"Am J Med"},{"key":"2023112102043498200_ehad584-B27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1470320313482603","article-title":"Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure","volume":"16","author":"Rossi","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehad584\/51267674\/ehad584.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/44\/4650\/53598374\/ehad584.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/44\/4650\/53598374\/ehad584.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:06:15Z","timestamp":1700532375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/44\/4650\/7251463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":27,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2023,8,26]]},"published-print":{"date-parts":[[2023,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad584","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,21]]},"published":{"date-parts":[[2023,8,26]]}}}